Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development.

Journal: Drug discovery today
PMID:

Abstract

Translational research has a crucial role in bridging the gap between basic biology discoveries and their clinical applications. Deep scientific understanding and advanced technology platforms are both crucial for translational research. Here, I describe a novel integrated Drug Intelligence Science (DIS®) translational platform that combines single cell technology with artificial intelligence (AI) and machine learning (ML) to gain insights into high-resolution cell biology, thus enabling the discovery of disease-relevant targets, high-quality drug candidates, and predictive biomarkers. The innovative DIS® approach has the potential to provide unprecedented mechanistic understanding of human diseases and enable in-depth pharmacological profiling of drug candidates to increase the probability of success (POS) in drug discovery and development.

Authors

  • Liang Schweizer
    HiFiBiO Therapeutics, 237 Putnam Avenue, Cambridge, MA 02139, USA. Electronic address: l.schweizer@hifibio.com.